China Stock Alerts
Legend Biotech Corp.
NASDAQ:
LEGN
Legend Biotech Corp. welcomes the opportunity to reinvigorate the treatment approaches in oncology and the future of cell therapy. Today, Legend Biotech's research is focused on continuous innovation in the field of cell therapy. Legend Biotech is also future focused on emerging technologies that can help address some of the most chronic and life-threatening diseases.
Key Facts
Auditor
Public Listing
Domicile
HQ/Management
Location of Key Operations
IR Contact
Ernst & Young LLP
IPO (June 5, 2020)
Cayman Islands
Somerset, NJ, USA
Jessie Yeung, Internal
Analyst Coverage
Latest News
September 23, 2021: Legend Biotech to Host R&D Day on October 18, 2021 - Legend Biotech
September 13, 2021: Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma - Legend Biotech
August 31, 2021: Legend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference - Legend Biotech
August 23, 2021: Legend Biotech Reports Second Quarter 2021 Financial Results and Recent Highlights - Legend Biotech
June 22, 2021: Legend Biotech Announces Advancement of Global Manufacturing Infrastructure - Legend Biotech
May 25, 2021: Legend Biotech to Present at the Jefferies Virtual Healthcare Conference - Legend Biotech
May 18, 2021: Legend Biotech Reports First Quarter 2021 Financial Results and Recent Highlights - Legend Biotech
May 10, 2021: Legend Biotech Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings - Legend Biotech
March 18, 2021: Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update
March 11, 2021: Legend Biotech Announces Fourth Quarter and Full-Year 2020 Earnings Conference Call
February 19, 2021: Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2020
February 1, 2021: Legend Biotech Announces BCMA CAR-T Therapy Cilta-cel Accepted for Accelerated Assessment in Europe for